• Skip to main content
  • Skip to primary sidebar

Biotech Briefings

  • Home
  • About
  • Editors
  • Topics
  • Subscribe
  • Home
  • About
  • Editors
  • Topics
  • Subscribe

Royalty Finance

Gibson Dunn and BCLT Host a Webcast Series on Royalty Finance, the UCC, and Issues of Recharacterization

May 12, 2025 | Posted by Todd J. Trattner; Ryan A. Murr; Topic(s): Royalty Finance

Gibson Dunn has partnered with the UC Berkeley Center for Law & Technology on a three-part webcast series that discusses issues originally raised in a Law 360 article on royalty financing written by partners Todd Trattner and Ryan Murr.

In the series, partners Todd Trattner, Ryan Murr, Jin Hee Kim, and Jeffrey Krause and associates Kali Jelen, Anthony Hajj, and Michael Farag provide an in-depth exploration of royalty finance, looking at synthetic royalties, the treatment of synthetics under the UCC, and the risks of a sale of a synthetic royalty being recharacterized as a loan in bankruptcy.

The series is designed to educate biotechnology stakeholders (investors, entrepreneurs, companies, and their attorneys) on best practices for monetizing and investing in a synthetic royalty so that they can embark on such transactions with greater certainty.

To access the series, visit:

  • Panel 1 – Royalty Finance: Structures, Trends and Synthetics
  • Panel 2 – Synthetic Royalty Financings and the UCC
  • Panel 3 – Synthetic Royalty Financings: Risks of Recharacterizing a True Sale (available May 20)

You can watch the series for free using the code “BCLT-GD” at checkout.

Tariffs and Royalties in License Agreements: Key Considerations for Life Science Companies

April 14, 2025 | Posted by Karen A. Spindler; Mary Beth Maloney; Topic(s): International Trade; Royalty Finance

Recent shifts in international trade policies have led to the imposition of new tariffs prompting life science companies to reassess their license agreements to understand the potential impact of these new tariffs on royalty calculations under such agreements.

Read More

Royalty Report: Royalty Finance Transactions in the Life Sciences 2020-2024

March 31, 2025 | Posted by Todd J. Trattner; Ryan A. Murr; Topic(s): Royalty Finance; Trends and Insights

This Royalty Report provides an analysis of publicly reported royalty finance transactions for the last five years (2020 to 2024) in the life sciences sector, focusing on both traditional and synthetic royalty transactions. Traditional royalty transactions encompass monetizations of royalties under existing license agreements. Synthetic royalty transactions involve the sale of a portion of future product sales, rather than the sale of an existing future royalty entitlement.

Read More

Introducing the Royalty Finance Tracker

March 19, 2025 | Posted by Todd J. Trattner; Ryan A. Murr; Topic(s): Royalty Finance; Trends and Insights

Dear friends and colleagues,

We are excited to introduce the Gibson Dunn Royalty Finance Tracker (https://www.gibsondunn.com/royalty-finance-tracker/) in conjunction with the launch of Biotech Briefings, where we have compiled all publicly announced royalty finance transactions amongst the most active funds that have occurred since January 1, 2020.

Read More

Key Takeaways: Life Sciences 2025 Outlook: Royalty Finance Webcast (March 12)

March 18, 2025 | Posted by Todd J. Trattner; Ryan A. Murr; Topic(s): Royalty Finance; Trends and Insights

Todd Trattner and Ryan Murr of Gibson Dunn and Doug Prescott of TD Cowen hosted a Life Sciences 2025 Outlook: Royalty Finance webcast on Wednesday, March 12, in which they provided an integrated outlook on royalty finance in the life sciences industry, identifying trends and uncertainties that will shape the year ahead.

Read More

How Biotech Cos. Can Utilize Synthetic Royalty Financing

February 2, 2024 | Posted by Todd J. Trattner; Ryan A. Murr; Topic(s): Royalty Finance; Trends and Insights

San Francisco of counsel Todd Trattner and partner Ryan Murr are the authors of “How Biotech Cos. Can Utilize Synthetic Royalty Financing” [PDF] published by Law360 on February 1, 2024.

Read More

Primary Sidebar

Gibson Dunn Life Sciences
2025 Outlook Webcast Series
Capital Markets: Click here to view the video recording and program materials.
Royalty Finance: Click here to view the video recording and program materials.
Read ROYALTY REPORT here.

Topics

Capital Markets

Clinical Trials

CVR Spinoff

CVRs

Delaware Law

ECVC

False Claims Act

FDA

FDA Guidance

Government Regulation

International Trade

IPOs

M&A

Manufacturing

Reverse Mergers

Royalty Finance

SEC Updates

Securities Litigation

Shareholder Activism

Trends and Insights

Editors

Rachel Baron

Branden C. Berns

Lindsay Bernsen Wardlaw

Aaron K. Briggs

Gustav W. Eyler

Hui Fang

Carlo Felizardo

Mark Goldman

Charlotte Jacobsen

Jin Hee Kim

Wynne Leahy

Jeff Lombard

Jane M. Love, Ph.D.

Mary Beth Maloney

Katlin McKelvie

James Moloney

Ryan A. Murr

Melanie E. Neary

John D.W. Partridge

Jonathan Phillips

Lindsey D. Schmidt

Samantha Sewall

Sam Shapiro

Adam Smith

Karen A. Spindler

Eric J. Stock

Hong Tran

Todd J. Trattner

Stephen Weissman

Useful Links

  • Gibson Dunn Website
  • Gibson Dunn Life Sciences Landing page
  • Securities Regulation and Corporate Governance Monitor
  • NVCA Model Legal Documents
  • Royalty Finance Tracker
  • Royalty Report: Royalty Finance Transactions in the Life Sciences 2020-2024
  • IPO Resource Center
  • IP Disputes and Litigation

Archives

Subscribe to Updates
RSS Feed
  • Privacy Statement
  • Cookie Notice
  • Contact Us
© 2025 Gibson, Dunn & Crutcher LLP. All rights reserved.